Disposition of 14295 shares by Alexander Hardy of Biomarin Pharmaceutical at 66.03 subject to Rule 16b-3
| FRBRX Fund | USD 141.38 6.06 4.11% |
Slightly above 61% of Franklin Biotechnology's investor base is looking to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are alarmed at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
Filed transaction by Biomarin Pharmaceutical Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Three Year Return
Three Year Return Comparative Analysis
Franklin Biotechnology is currently under evaluation in three year return among similar funds. Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| SBQAX | Americafirst Large | 0.49 |
| ||
| TWQZX | Transamerica Large | 0.59 |
| ||
| VAAGX | Virtus Nfj | 0.66 |
| ||
| DOXGX | Dodge Cox | 0.67 |
| ||
| GMLVX | Guidemark Large | 1.37 |
| ||
| PCLVX | Pace Large | 2.54 |
| ||
| LMISX | Qs Large | 3.27 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |